Effect of Human Amniotic Epithelial Cells on Children With Spastic Cerebral Palsy
NCT ID: NCT03107975
Last Updated: 2017-04-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
10 participants
INTERVENTIONAL
2017-04-01
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Cerebral Palsy
NCT03078621
Transplantation of Umbilical Cord-derived Mesenchymal Stem Cells Via Different Routes
NCT03414697
MSCs Therapy for Cerebral Palsy
NCT04653077
Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Intravenous Infusion for CP
NCT05018871
Outcomes of Stem Cells for Cerebral Palsy
NCT02569775
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study aimed to evaluate the therapeutic potential of human amniotic epithelial cell (hAEC) transplant in the management of children with spastic cerebral palsy. hAEC will be intrathecal transplanted. Functional status is determined by Gross Motor Function Measure-66 and Fine Motor Function Measure. Spasticity is evaluated by using modified Ashworth scale(MAS).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cell Therapy
intrathecal injection of human amniotic epithelial cells
human amniotic epithelial cells
intrathecal injection of human amniotic epithelial cells
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
human amniotic epithelial cells
intrathecal injection of human amniotic epithelial cells
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gross Motor Function Classification System (GMFCS) levels III-V;
* Parents accepted voluntarily cell therapy for their children and followed-up.
Exclusion Criteria
* Serological tests such as AIDS, hepatitis B, syphilis, etc;
* Hereditary metabolic diseases of nervous system;
* Tumor or Hematological diseases.
1 Year
5 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
INDUSTRY
The Second Affiliated Hospital of Fujian Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hongzhi Gao, Dr.
Role: PRINCIPAL_INVESTIGATOR
The Second Affiliated Hospital of Fujian Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Affiliated Hospital of Fujian Medical University
Quanzhou, Fujian, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SC-CP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.